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Objective: The purpose of this study was to compare the usefulness of the Nottingham Health Profile (NHP) and the
Short-Form 36 Health Survey (SF-36) as general outcome measures after vascular intervention for lower limb ischemia
with respect to patients’ quality of life, on the basis of validity, reliability, and responsiveness analyses.
Patients and Methods: Eighty patients, 40 with claudication and 40 with critical ischemia, were assessed before and one
month after revascularization by using comparable domains of the NHP and the SF-36 questionnaires.
Results: The SF-36 scores were less skewed and were distributed more homogeneously than the NHP scores. Discriminate
validity results showed that NHP was better than SF-36 in discriminating among levels of ischemia with respect to pain
and physical mobility. For both questionnaires, the reliability standards were satisfactory in most respects. The NHP was
more responsive than the SF-36 in detecting within-patient changes. All of the NHP domains not zero at baseline were
improved significantly one month after hemodynamically successful revascularization for patients with claudication,
whereas patients with critical ischemia showed significant abatement of pain and improvements in physical mobility and
social isolation. The SF-36 scores indicated a significant decrease in bodily pain and improvements in physical functioning
and vitality for patients with claudication, and decrease in bodily pain and improvement in physical functioning for
patients with critical ischemia.
Conclusions: The findings indicated that both NHP and SF-36 were reliable. The SF-36 scores were less skewed than the
NHP scores, whereas NHP discriminated better among levels of ischemia and was more responsive in detecting
quality-of-life changes over time than SF-36 in these particular patients. (J Vasc Surg 2002;36:310-7.)
The fact that one of the primary goals of vascular
surgical intervention is to improve patients’ quality of life
calls for a sensitive measurement of the outcome.
Intermittent claudication is a common problem, with a
prevalence of 14% in men older than 68 years from a general
Swedish population, and it is estimated that approximately
15% to 20% will progress to critical ischemia.1 It is known
that there is a spectrum of symptoms that affects the lives of
these patients—such as claudication or ischemia rest pain,
reduced mobility, sleep disorders, and ulceration or gan-
grene2,3—related to the severity of the disease.4,5 To inves-
tigate the need for and efficacy of vascular intervention, a
measure is required that is applicable at different levels of
the disease and capable of detecting changes in quality of
life over time.
Traditionally, the success of a particular intervention
has been described in terms of graft patency and limb
salvage.6 However, these data do not provide information
on the ultimate effect of intervention on patients’ quality of
life. Moreover, the relatively weak correlations among ankle
pressure, walking distance, and quality of life found in
earlier studies7,8 indicate that quality-of-life outcome fo-
cuses on aspects of the disease other than lower limb
perfusion. Two types of instruments measure quality of life:
disease-specific and generic.9 Generic instruments such as
the Nottingham Health Profile (NHP) and the Short-Form
36 Health Survey (SF-36) are applicable to a wide variety of
populations because they address multidimensional aspects
such as physical functioning, emotion or mood, social
functioning, role performance, pain, and commonly per-
formed daily activities.10 Disease-specific instruments such
as the Walking Impairment Questionnaire11 have been
developed for patients with claudication, and they address
specific aspects including the degree of pain, aching, or
cramps; reason for the difficulty in walking; walking dis-
tance; walking speed; and stair climbing. At present, no
accurate disease-specific instrument exists to evaluate pa-
tients with critical ischemia. In previous research, different
generic instruments have been used to analyze changes in
quality of life following vascular intervention, including the
NHP12 and the SF-36.13 The main limitation of the NHP
scale with regard to sensitivity is the “floor effect,” whereby
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patients with milder symptoms tend to score zero or near
zero and are, therefore, unsuitable for use in examining
improvements.14 On the other hand, bodily pain evaluated
in the SF-36 scale has been noted to correlate weakly with
a clinically reported knee pain scale.15 To date, no study has
from the same sample analyzed these two instruments to
determine which is most appropriate with regard to its
responsiveness in detecting clinical changes following vas-
cular intervention.
To be useful in clinical practice, a generic outcome
measure for patients with vascular disease needs to satisfy
different criteria. One consideration regarding validity is an
instrument’s ability to measure differences between pa-
tients with various degrees of lower limb ischemia. Another
important characteristic is reliability. One aspect of reliabil-
ity refers to the extent to which all of the items on the
instrument measure the same underlying attribute.16 Fi-
nally, perhaps the most important property of a generic
outcome measure is its responsiveness in detecting clinical
within-patient changes following vascular intervention. For
the purpose of providing recommendations about the use-
fulness of these instruments as generic outcome measures
for these particular patients, empiric comparison of psycho-
metrics, features, and performance are needed. The aim of
this study was to compare the usefulness of the NHP and
the SF-36 as general outcome measures after vascular inter-
vention for lower limb ischemia with respect to patients’
quality of life, on the basis of validity, reliability, and
responsiveness analyses.
PATIENTS AND METHODS
Patients. One hundred consecutive patients from one
Swedish academic vascular surgery unit in southern Sweden
were invited to participate in the study. Inclusion criteria
were admission for active treatment of documented lower
limb ischemia, no communication difficulties, and no other
treated disease in the system of the lower limbs restricting
walking capacity. Of 100 patients, twenty (20%) dropped
out for various reasons, 16 (16%) did not wish to partici-
pate, 3 (3%) had other complications, and one (1%) patient
died during follow-up. Thus, the quality-of-life analyses
were performed on 80 (80%) patients at baseline and one
month after percutaneous transluminal angioplasty (PTA)
or surgical revascularization. The selection criterion for
“hemodynamically successful” was that the ankle-brachial
pressure index (ABPI) increased by 0.15 or more at one
month.17 The severity of patients’ lower limb ischemia was
graded according to suggested standards for reporting
grade of lower limb ischemia.17 Forty (50%) patients with
claudication and 40 patients with critical ischemia were
treated by using a surgical bypass graft (73.8%) or by PTA
(26.2%).
Clinical parameters. At baseline, routine medical his-
tory and risk factors were obtained in accordance with the
Swedish Vascular Registry (Swedvasc),18 and clinical exam-
inations were performed. At the one-month follow-up
these measurements were repeated. Palpable pulse, ankle-
brachial pressure (ABP), and ABPI were reported. The
ABPI was calculated by taking the ABP on the treatment
side and dividing it by the highest arm pressure. For pa-
tients with claudication, a standard treadmill test (3 km/
hour with a 14% incline) was performed at baseline and at
the one-month follow-up.
Nottingham Health Profile. The NHP was devel-
oped as a measure of perceived distress relating to poten-
tially disabling health conditions.19 The NHP is a two-part
instrument; part I was used in this study. The 38 yes-no
items of part I reflect the patient’s degree of distress within
the domains of pain, physical mobility, emotional reactions,
energy, social isolation, and sleep. The answers to the
Swedish items are weighted,20,21 giving a range of possible
scores from zero (indicating no problems at all) to 100
(indicating the presence of all problems within a domain).
The Swedish version of the NHP is the most frequently
used and best evaluated and has been shown to be reliable
and valid in different patient groups.22,23 The NHP scale
has also shown responsiveness to changes associated with a
variety of treatments such as recovering from limb frac-
ture,24 heart/lung transplantation,25 and after successful
revascularization in patients with lower limb ischemia.12
Short-Form 36 Health Survey. The SF-36 was de-
veloped from a previous questionnaire known as the Med-
ical Outcome Study General Health Survey Instrument.26
It contains 36 items covering eight health domains: bodily
pain, physical function, role limitations due to physical
problems, mental health, vitality, social function, role lim-
itations due to emotional problems, and general health.
Items in two scales are answered in a yes-no format. For the
other scales, patients are asked to answer on a three-to-six
response scale. For each scale, item scores are summed and
transformed into a scale from zero (indicating worse health
state) to 100 (indicating best health state). For this study
the standard Swedish version of the SF-36 was used.27 In
population studies as well as in other patient groups, the
SF-36 has been found to be acceptable with regard to
validity and reliability.15,28,29 The responsiveness of the
SF-36 to changes in health status over time has been shown
in patients with critical ischemia following infrainguinal
reconstruction.13,30
Procedure. All patients had given prior consent to
participate in the study. During their initial admission,
patients were asked by the head nurse to fill out the NHP
and the SF-36 questionnaires by themselves, before and
one month after intervention. This study followed the
routine of follow-up periods in accordance with the Swed-
vasc guidelines.18 Demographic characteristics and history
of clinical data were obtained from the patients’ medical
record. Approval for the study was obtained in advance
from the ethics committee of the University of Lund.
Statistical analyses. Analysis of differences in baseline
characteristics between patients with claudication and those
with critical ischemia were based on chi-square and Mann-
Whitney U tests. The prevalence of patients achieving the
lowest (floor effect) and highest (ceiling effect) possible
quality-of-life score in NHP and SF-36 was also calculated.
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The validity was examined by the Mann-Whitney U test
regarding the relative ability of the two instruments to
discriminate among levels of lower limb ischemia. The
analysis focused on those domains that are comparable
between the two instruments, including physical mobility,
pain, energy, social isolation, and emotional reactions for
the NHP, and physical functioning, bodily pain, vitality,
social functioning, and mental health for the SF-36 (Table
I). Furthermore, a logistic regression analysis (forward
stepwise method) was used to determine which of the five
comparable domains in the NHP and SF-36 differentiated
between patients with claudication and those with critical
ischemia. For this purpose, clinical data, the level of pa-
tients’ ABPI at baseline, and walking distance for patients
with claudication were used as the criteria for disease sever-
ity. Each domain for the NHP and SF-36 was divided
according to the median value.
Internal consistency based on correlations between
items for each scale was measured by using Cronbach’s .31
There are two ways to report internal consistency: one is to
show the  value and the other is to show the reliability
coefficient. A reliability coefficient in the vicinity of 0.70 is
reported to be a recommended reliability standard for
group-level comparisons, whereas ideally, decisions about
Table I. Domains measured by the Nottingham Health Profile and the Short Form 36
Domain Nottingham Health Profile SF-36
Pain Pain (8 items) Bodily pain (2 items)
Physical activity Physical mobility (8 items) Physical functioning (10 items)
Psychological status Emotional reactions (9 items) Mental health (5 items)
Energy (3 items) Vitality (4 items)
Social activity Social isolation (5 items) Social functioning (2 items)
Other Sleep General health
Physical role
Emotional role
Comparable domains shown in italics.
Table II. Patients’ demographic characteristics and clinical indicators at baseline
Claudication
(n  40)
Critical ischemia
(n  40)
Total
(n  80) P value
Mean age (SD)* 67 (11) 71 (10) 69 (10) .04
Sex (%)† NS
Male 21 (52.5) 20 (50) 41 (51.3)
Female 19 (47.5) 20 (50) 39 (48.8)
Severity of disease (%)
Moderate claudication 2 (5) 2 (2.5)
Severe claudication 38 (95) 38 (47.5)
Ischemia rest pain 20 (50) 20 (25)
Ischemia ulcers 17 (42.5) 17 (21.2)
Gangrene 3 (7.5) 3 (3.8)
Level of disease (%)
Iliac 17 (42.5) 12 (30) 29 (36.2)
Femoral (above knee) 18 (45) 10 (25) 28 (35)
Below knee (distal) 5 (12.5) 18 (45) 23 (28.8)
Leg side of disease (%) NS
Unilateral 37 (92.5) 32 (82.1) 69 (86.2)
Bilateral 3 (7.5) 8 (17.9) 11 (13.8)
Type of intervention (%)† .04
Angioplasty (PTA) 15 (37.5) 6 (15) 21 (26.2)
Surgical revascularization 25 (62.5) 34 (85) 59 (73.8)
Risk factors (%)†
Smoking 7 (17.5) 9 (22.5) 16 (20) NS
Stroke/TIA 4 (10) 1 (2.5) 5 (6.3) NS
Diabetes 4 (10) 11 (27.5) 15 (18.8) NS
Hyperlipidemia 1 (2.5) 1 (2.5) 2 (2.5) NS
Hypertension 12 (30) 14 (35) 26 (32.5) NS
Heart disease 7 (17.5) 16 (40) 23 (28.8) .04
Chronic lung disease 1 (2.5) 3 (7.5) 4 (5) NS
Kidney disease 1 (2.5) 2 (5) 3 (3.8) NS
NS, Not significant; SD, standard deviation; TIA, transient ischemic attack.
*Tested by Mann-Whitney U test.
†2 test.
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individuals should be based on a reliability coefficient of
0.90 or better.16
The responsiveness of the two instruments in detecting
within-subject changes over time in the group as a whole as
well as in patients with claudication and those with critical
ischemia was analyzed with use of the Wilcoxon signed rank
test. The correlation between quality of life scores, ABPI,
type of intervention, age, and gender was analyzed by using
the Spearman rank correlation. Data analysis was per-
formed by using the statistical package SPSS 8.0 (Lund,
Sweden) for overall comparison, and a two-tailed P value
of .05 was considered statistically significant.32
RESULTS
Of 80 patients, 64 patients had a hemodynamically
successful revascularization, whereas 16 had an unsuccess-
ful revascularization. Statistically significant differences in
age were found, showing that patients with critical ischemia
were older than patients with claudication (P  .04)
(Table II). Angioplasty was significantly more common in
patients with claudication, whereas patients with critical
ischemia more often had surgical revascularization (P 
.04). In addition, a history of heart disease (P  .04) was
significantly higher among patients with critical ischemia
than among patients with claudication (Table II). After
successful revascularization there was a significant improve-
ment in walking distance (P  .0001) for patients with
claudication. There were no significant differences in qual-
ity of life (NHP and SF-36) between patients who had
undergone PTA (n  11) and those who had undergone
surgery (n  53). No significant correlation was found
between the measured quality-of-life domains and ABPI,
walking distance for patients with claudication, age, or sex.
Comparison of the frequency distribution of NHP and
SF-36 scores on the comparable domains showed that the
NHP scores were more skewed than the SF-36 scores (Fig
1). The prevalence of patients with best possible scores,
referred to as “ceiling effect” (SF-36  100; NHP  0),
was higher for the NHP scale (range, 1.3%-65%) than for
the SF-36 scale (range, 0%-16.3%). The prevalence of worst
possible scores, “floor effect” (SF-36  0; NHP  100),
was also higher for the NHP scale (range, 0%-28.8%) than
for the domains of SF-36 (range, 0%-6.3%) (Table III).
Validity. Increasing lower limb ischemia resulted in a
significant deterioration in NHP-measured quality-of-life
domains with regard to pain (P .01) and physical mobil-
ity (P  .03), indicating lower quality of life at baseline in
patients with critical ischemia (Table IV). Emotional reac-
tions, energy, and social isolation were domains assessed by
the NHP not influenced significantly by increasing lower
limb ischemia. None of the domains assessed by the SF-36
was influenced significantly by increasing lower limb isch-
emia. Further analysis showed that belonging to the critical
ischemia group was significantly associated with high pain
scores of the NHP (odds ratio, 9.7; 95% confidence inter-
val, 2-47.1; P  .004). Physical mobility, emotional reac-
tions, energy, and social isolation for the NHP and all of the
SF-36 domains failed to reach statistical significance as
independent factors.
Reliability. All domains measured by the two instru-
ments were statistically reliable, with  values of 0.70,
except for the NHP-measured social isolation (  .60)
Fig 1. Frequency distribution of scores on the NHP (left panel)
and comparable dimensions on the SF-36 (right panel).
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and for the SF-36-measured bodily pain (  .69) and
social functioning ( .68) (Table III). The SF-36 showed
the highest reliability of the two instruments tested, attain-
ing  values of0.90 in physical functioning and of0.83
in mental health.
Responsiveness. The ability to detect significant qual-
ity-of-life changes between baseline and the one-month
follow-up was not equally good in all domains for the NHP
and SF-36 (Table V). All of the comparable domains mea-
sured by the NHP improved significantly in the 64 patients
one month after hemodynamically successful revasculariza-
tion. For the SF-36-measured domains there were signifi-
cant improvements in bodily pain (P  .0001), physical
functioning (P  .0001), and vitality (P  .04), whereas
mental health and social functioning showed no significant
improvements. One month after hemodynamically unsuc-
cessful revascularization, the 16 patients had a significantly
lower score in energy (P  .007) and emotional reactions
(P  .02) measured by the NHP, whereas the SF-36
showed significant improvements in physical functioning
(P  .02). The 31 patients with claudication had one
month after hemodynamically successful revascularization
significant improvements in all NHP-measured quality-of-
life domains that were not zero at baseline, whereas the 33
patients with critical ischemia had improvements in pain
(P  .0001), physical mobility (P  .0001), and social
isolation (P  .02), but not in emotional reactions and
energy (Fig 2). The SF-36-measured quality-of-life do-
mains showed significant improvements in bodily pain (P
.001), physical functioning (P  .0001), and vitality (P 
.03) for patients with claudication, and in bodily pain (P
.004) and physical functioning (P  .01) for patients with
critical ischemia, whereas mental health and social func-
tioning were not improved in any of the subgroups (Fig 3).
After hemodynamically unsuccessful revascularization, none
of the patients showed significant improvements in quality
of life, except for in emotional reactions (P  .04) and
energy (P  .04) for patients with claudication measured
by the NHP.
DISCUSSION
Findings indicated that the SF-36 scores were less
skewed and more homogeneously distributed than the
NHP scores. Discriminate validity results, however,
showed that NHP was better than SF-36 in discriminating
among levels of ischemia with regard to pain and physical
mobility. For both questionnaires, the reliability standards
were satisfactory in most respects. The NHP questionnaire
was more responsive than the SF-36 in detecting within-
patient changes. All of the NHP domains not zero at
baseline were significantly improved one-month after he-
modynamically successful revascularization for patients
with claudication, whereas patients with critical ischemia
showed improvements in pain, physical mobility, and social
isolation. The SF-36 questionnaire detected improvements
in bodily pain, physical functioning, and vitality for patients
with claudication and in bodily pain and physical function-
ing for patients with critical ischemia.
The NHP and the SF-36 are both generic instruments
for assessing health-related quality of life.9 They have been
tested extensively and used for different purposes in many
populations, including patients with lower limb isch-
emia.4,12 For the purpose of assessing the utility of these
instruments as general outcome measures in clinical prac-
Table III. Comparison of “floor” and “ceiling” effects and reliability in comparable NHP and SF-36 scales
NHP* Floor Ceiling  values† SF-36 Floor Ceiling  values
Pain 6.3 3.8 .77 Bodily pain 6.3 0 .69
Physical mobility 0 1.3 .73 Physical functioning 2.5 0 .90
Emotional reactions 0 38.8 .78 Mental health 0 3.8 .83
Energy 28.8 27.5 .71 Vitality 5 0 .71
Social isolation 0 65 .60 Social functioning 0 16.3 .68
Data are percentages unless otherwise indicated.
*The NHP scores are reversed for consistency with the SF-36.
†Cronbach’s .
Table IV. Differences in NHP- and SF-36-measured
quality of life domains between patients with claudication
and those with critical ischemia at baseline
Domain
Claudication
(n  40)
Critical ischemia
(n  40)
Md(q1,q3) Md(q1,q3)
P
value*
NHP†
Pain 37.6 (27.3-56.6) 53.7 (27.8-87.4) .01
Physical mobility 32.8 (10.2-52.4) 48.7 (21.7-67.3) .03
Emotional reactions 11.1 (0-42.2) 8.8 (0-25.6) .39
Energy 60.6 (5.9-100) 60.6 (0-100) .59
Social isolation 0 (0-25.1) 0 (0-25.1) .99
SF-36‡
Bodily pain 36.5 (22-42) 31 (22-41) .4
Physical functioning 25 (15-40) 25 (15-43.8) .84
Mental health 66 (52-83) 66 (49-76) .73
Vitality 42.5 (31.3-60) 45 (21.3-58.8) .49
Social functioning 68.8 (50-87.5) 62.5 (50-75) .43
*Mann-Whitney U test.
†Score 100, a high score indicates a greater perceived health problem.
‡Score 100, a high score indicates a smaller perceived health problem.
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tice for vascular surgery there are different criteria that have
to be taken into consideration. First, the questionnaire
should be brief and easy to use. The NHP and the SF-36
seemed to meet that criterion, requiring just 10 minutes
each to complete. Secondly, the questionnaire should be
acceptable for use by older patients. This acceptance was
indicated by the high response rate of 80%. Brazier et al,29
however, reported a high level of missing data for the SF-36
in persons over 65 years of age. Lastly, the study design
might be limited by the fact that the NHP and the SF-36
questionnaire domains differ in their nature and content.
Nevertheless, consistent with the World Health Organiza-
tion10 both questionnaires include basic domains of phys-
ical, social, and mental health.
It is widely accepted that the more homogeneous the
distribution of scores, the lower the floor and ceiling ef-
fects, the better the measuring instrument.16 Although
both questionnaires provided nonsymmetric distributions,
the analysis showed that the responses to the SF-36 ques-
tionnaire were less skewed and more homogeneously dis-
tributed than the responses to the NHP. Similarly, Prieto et
al33 showed that SF-36 was less skewed and exhibited a
more homogeneous distribution of scores (other than for
mental health) than the NHP in patients with chronic
obstructive pulmonary disease. Furthermore, the two ques-
tionnaires differed somewhat in their measurement of the
full range of health. Four of the SF-36–measured but only
two of the NHP-measured domains achieved recom-
Fig 2. Changes in median score for the NHP in claudicants
(n  31) and patients with critical ischemia (n  33), before
(gray bars) and one month after (black bars) successful revascular-
ization. Pain (P), physical mobility (PM), emotional reactions
(EM), energy (E), and social isolation (SO). Analyzed with use of
Wilcoxon signed rank test. A higher score indicates greater per-
ceived health problems. *P  .05; **P  .01; ***P  .001.
Fig 3. Changes in median score for the SF-36 in claudicants (n
31) and patients with critical ischemia (n 33), before (gray bars)
and one month after (black bars) successful revascularization.
Bodily pain (BP), physical functioning (PF), mental health (MH),
vitality (VT), and social functioning (SF). Analyzed with use of
Wilcoxon signed rank test. A higher score indicates less perceived
health problems. *P  .05; **P  .01; ***P  .001.
Table V. Changes in NHP- and SF-36–measured quality of life domains, before and 1 month after hemodynamically
successful revascularization in patients with lower limb ischemia
Domain
NHP*
Domain
SF-36†
Md (q1,q3)‡ P value§ Md (q1,q3) P value
Pain 20.7 (0-36.2) .0001 Bodily pain 10 (0-31) .0001
Physical mobility 13.9 (0-29) .0001 Physical functioning 10 (0-25) .0001
Emotional reactions 0 (0-11.8) .04 Mental health 4 (8-12) .77
Energy 0 (0-39.4) .02 Vitality 2.5 (5-18.8) .04
Social isolation 0 (0) .002 Social functioning 0 (12.5-9.4) .26
*Score 100, a high score indicates a greater perceived health problem.
†Score 100, a high score indicates a smaller perceived health problem.
‡Changed median values (25th and 75th percentiles).
§Wilcoxon signed rank test.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 2 Klevsgård et al 315
mended standards of score distributions (15%).34 Both
questionnaires exhibited minor floor effects. However, the
NHP showed higher ceiling effects than the SF-36 regard-
ing social isolation, emotional reactions, and energy. Pre-
viously, Prieto et al33 reported less ceiling and floor effects
in SF-36 than in NHP, whereas McHorney et al35 reported
very small floor effects for SF-36 in diverse patient groups.
In addition, substantial ceiling effects have been reported
for the NHP, ranging from 48% to 78% in community-
based studies.29,36 The superiority of the SF-36 question-
naire in this respect may be the result of increasing number
of possible different scores, whereas NHP items are based
on dichotomous responses (yes/no) and the measuring of
items tap more extremes end of ill health.
All domains measured by the two instruments exceeded
the minimum reliability of0.70 recommended for group
comparisons,16 except bodily pain (  .69) and social
functioning (  .68) for SF-36, and social isolation ( 
.60) for NHP. Physical functioning ( .90) for the SF-36
was the only domain that met the minimum standard for
individual-level application of 0.90 to 0.95.16 Previously,
Wiklund et al22 reported reliability coefficients of 0.81 to
0.34 for the NHP in patients with arthrosis of the hip joint,
and McHorney et al35 showed reliability coefficients of
0.93 to 0.82 for the SF-36 across diverse patients group.
However, in a study if patients with lower limb ischemia,
Chetter et al4 indicated that the NHP might be more
reliable than the SF-36, attaining reliability coefficients of
0.80 for all of the NHP domains. These findings suggest
that although both questionnaires meet the reliability stan-
dards for group-level application in most respects, none of
them achieved the degree of reliability that would be desir-
able in individual-based assessment and decision-making,
except for physical functioning.
In terms of validity, the questionnaires should be suffi-
ciently sensitive to discriminate between levels of disease.16
Surprisingly, the result showed that the NHP questionnaire
was better than SF-36 at discriminating between levels of
ischemia, indicating significant deterioration in the do-
mains of pain and physical mobility in patients with critical
ischemia. Nevertheless, Chetter et al4 found that SF-36 and
NHP were equally responsive to variations in physical ac-
tivity and pain, whereas SF-36 was more responsive to
variations in psychological status. In addition, Prieto et al33
suggested that both instruments were similar in discrimi-
nating among different levels of respiratory impairment.
The small sample size in the subgroups in this study may be
one explanation of the absence of the ability for the two
instruments to discriminate among levels of ischemia. De-
spite the fact that the NHP score had more skewed distri-
bution, these findings suggest that the NHP is more sensi-
tive in explaining the quality-of-life phenomena in these
particular patients with respect to pain and physical mobil-
ity.
Perhaps one of the most important characteristics of an
effective outcome measure is the instrument’s ability to
detect changes in general health over time. The analysis
showed that NHP was most responsive to within-patient
changes, indicating immediate improvements after hemo-
dynamically successful revascularization in all measured
domains, whereas SF-36 showed improvements in all do-
mains, except for social functioning and mental health. The
responsiveness in detecting changes in the subgroups was
also in favor of the NHP. The NHP questionnaire has
previously shown improvements for patients with claudica-
tion in all health domains that were not zero at baseline
after a hemodynamically successful bypass grafting or an-
gioplasty.12 Whereas Chetter et al reported improvements
in all the SF-36 measured domains for patients with clau-
dication30 and significantly improved physical functioning,
pain, vitality, and social functioning for patients with criti-
cal ischemia.13 These results suggest good responsiveness
for the NHP in general quality-of-life changes based on
short-time evaluation. However, one-month follow-up
may be too short a period for recovery from a surgical
procedure, and the essentials of measuring within-patient
changes should, therefore, also have evidence pertaining to
the responsiveness of quality-of-life changes in longitudinal
studies. Furthermore, generic quality-of-life questionnaires
such as NHP and SF-36 are global in their nature, and
improvements in functional status are often difficult to
define, especially in patients with critical ischemia, because
of the presence of numerous and often severe comorbid
conditions. Therefore, disease-specific instruments capable
of detecting improvements in functional status and predict-
ing and selecting patients with critical ischemia may be
needed.37
In conclusion, the findings indicated that both NHP
and SF-36 were reliable. The SF-36 scores were less skewed
than the NHP scores, whereas NHP discriminated better
among levels of ischemia and was more responsive in de-
tecting quality of life changes over time than SF-36 in these
particular patients.
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